The most selected trigger is documented axial length progression, showing that structural change is beginning to outweigh refraction alone..
Ophthalmology Insight Report
Childhood Myopia in Practice: Why Eye Specialists Treat Earlier, But Still Struggle to Measure Progression
A global MDForLives survey of ophthalmology respondents shows a field moving from diopter-based correction toward structural disease interception. Yet the same data reveals practical friction around optical biometry, atropine formulation choices, light therapy safety, and packaged multimodal care.
SGID 8871813
Audience: Ophthalmology
Total: 41
Completion: 70.7%
-Hero finding
0
%
selected a structural, progression, percentile, or hereditary trigger rather than relying on refraction alone.
cautious RLRL use only
0
%
do not fully use biometry as the active decision-maker
0
%
positive toward co-managed bundles
0
%
move beyond simple 0.01% atropine monotherapy
0
%
– Quick Read — Key Findings
See the full peer insight report
Explore how ophthalmologists balance early intervention, measurement gaps, safety thresholds, and multimodal therapy in childhood myopia control.
//The core signal
Childhood myopia is being treated less like optical correction and more like structural risk management.
The central pattern in this survey is a shift in what eye specialists consider clinically meaningful. Refraction still matters, but it is no longer the only trigger. When 69.5% of responses across the source percentages fall into kinetic, percentile, or hereditary pathways, the field appears to be moving toward earlier interception of axial elongation risk.
This matters because parents and patients often understand myopia as a glasses problem, while clinicians increasingly frame it as a long-term retinal and structural risk problem. That creates a communication gap. The child may have only mild blur, but the clinician may already be seeing a future high-risk trajectory.
The refractive number is no longer the whole story. In this survey, axial growth and risk trajectory begin to define when clinicians feel intervention is justified.
MDForLives synthesis
structural, kinetic, percentile, or hereditary trigger
0
%
refractive trigger only
0
%
kinetic progression trigger
0
%
percentile curve trigger
0
%
//Chart one
Where does intervention begin?
The largest single group waits for an aggressive progression curve, but the broader picture is more important: a majority of respondents locate risk outside refraction alone.
//Therapeutic grey zone
Atropine strategy is split between tolerability, stronger dosing, and combination care.
The atropine data does not show one dominant pharmacologic consensus. It shows a practice community negotiating between the low side-effect comfort of 0.01%, the stronger efficacy logic of 0.025% or 0.05%, adjunct use with optical defocus, and concern over compounding quality.
63.7%
selected approaches that move beyond simple continued 0.01% atropine monotherapy, based on the sum of higher concentration, adjunct-only, and standardized commercial-product preference responses.
//Safety threshold
RLRL sits in a clinical tension between promising efficacy and retinal safety caution.
Only 9.1% actively prescribe RLRL as an efficacy-led strategy, while 57.6% reserve it for cautious off-label or investigational use and 33.3% strictly avoid it. That pattern does not reject innovation. It indicates that pediatric retinal safety and medical-legal risk set a high bar for adoption.
//Diagnostic bottleneck
Biometry is recognized, but it is not yet universally decisive.
Only 21.9% report measuring axial length on every pediatric patient and actively altering care based on millimeter growth. The rest either continue to let refraction decide, face acquisition barriers, or do not see axial length monitoring as necessary. The result is a structural-disease framework operating inside a partially refractive-care infrastructure.
//Commercial-clinical interface
Co-managed bundles may work when they reduce burden, not when they limit judgment.
The 59.4% positive response toward pharma-optical bundles suggests clinicians see value in easier onboarding, parent compliance, and cost simplification. Yet 28.1% are neutral and 12.5% are negative, showing that adoption depends on whether bundles support customization rather than replacing it.
//Open-ended signal
When progression becomes aggressive, clinicians reach for combination therapy.
In the open-ended escalation vignette, atropine was repeatedly mentioned, often alongside optical defocus, myopia-control contact lenses, orthokeratology, axial-length follow-up, outdoor time, or specialist referral. The peer pattern is clear: for a high-risk 7-year-old with aggressive axial growth, many clinicians would not rely on one modality alone.
“Start 0.05% low dose atropine… in addition to peripheral defocus spectacles and recheck in 3 months.”
Open-text response example
// at a glance
Total Survey Records
41
Countries Covered
5
Specialty
Ophthalmologists
Published Date
13 June 2026
Completion Rate
70.7%
Survey ID
8871813
// browse categories
Endocrinology, Diabetes & Metabolism
7
Oncology & Hematology
7
Hospital Administration
6
Dermatology
6
Ophthalmology
6
Gastroenterology & Hepatology
6
Pharmacy
6
Primary Care & Family Medicine
6
Surgery & Procedural Care
5
Diabetes, Weight & Metabolic Health
5
Neurology
5
Dentistry & Oral Health
5
Nurses, NPs & Physician Assistants
5
Pediatrics
5
Cardiology
4
Laboratory & Diagnostics
4
Radiology & Imaging
3
Optometry & Optical Care
3
Skin & Aesthetic Care
2
Cancer Care
1
Social Work & Patient Support
1
Brain, Nerves & Mental Health
1
You have read the summary
Go beyond the Summary.
Help shape what we understand next.
Dive deeper into the research, or take part in future studies that turn real healthcare perspectives into meaningful insights.
Related Reports
